CN115736259A - 可改善肌肉力量的组合物及其在食品中的应用 - Google Patents
可改善肌肉力量的组合物及其在食品中的应用 Download PDFInfo
- Publication number
- CN115736259A CN115736259A CN202211528940.9A CN202211528940A CN115736259A CN 115736259 A CN115736259 A CN 115736259A CN 202211528940 A CN202211528940 A CN 202211528940A CN 115736259 A CN115736259 A CN 115736259A
- Authority
- CN
- China
- Prior art keywords
- casein
- composition
- content
- food
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000013305 food Nutrition 0.000 title claims abstract description 30
- 239000000203 mixture Substances 0.000 title claims abstract description 28
- 210000003205 muscle Anatomy 0.000 title claims abstract description 20
- 108010076119 Caseins Proteins 0.000 claims abstract description 22
- 102000011632 Caseins Human genes 0.000 claims abstract description 22
- 239000005018 casein Substances 0.000 claims abstract description 21
- 108090000942 Lactalbumin Proteins 0.000 claims abstract description 8
- 102000004407 Lactalbumin Human genes 0.000 claims abstract description 8
- 108010067454 caseinomacropeptide Proteins 0.000 claims abstract description 8
- 235000021241 α-lactalbumin Nutrition 0.000 claims abstract description 8
- 235000021247 β-casein Nutrition 0.000 claims abstract description 8
- 235000016709 nutrition Nutrition 0.000 claims description 22
- 102000007544 Whey Proteins Human genes 0.000 claims description 13
- 108010046377 Whey Proteins Proteins 0.000 claims description 13
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 13
- 235000021240 caseins Nutrition 0.000 claims description 13
- 235000021119 whey protein Nutrition 0.000 claims description 13
- 229940024606 amino acid Drugs 0.000 claims description 9
- 150000001413 amino acids Chemical class 0.000 claims description 9
- 235000018102 proteins Nutrition 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 7
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 7
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 7
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 7
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 7
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 7
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 7
- 229960000310 isoleucine Drugs 0.000 claims description 7
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 7
- 239000004474 valine Substances 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims description 2
- 239000000047 product Substances 0.000 description 36
- 208000015380 nutritional deficiency disease Diseases 0.000 description 19
- 208000002720 Malnutrition Diseases 0.000 description 17
- 235000000824 malnutrition Nutrition 0.000 description 17
- 230000001071 malnutrition Effects 0.000 description 17
- 235000005911 diet Nutrition 0.000 description 13
- 235000013350 formula milk Nutrition 0.000 description 11
- 230000035764 nutrition Effects 0.000 description 11
- 230000037213 diet Effects 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 201000010099 disease Diseases 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 235000015097 nutrients Nutrition 0.000 description 8
- 230000008859 change Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 6
- 102000014171 Milk Proteins Human genes 0.000 description 5
- 108010011756 Milk Proteins Proteins 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 239000000039 congener Substances 0.000 description 5
- 235000015872 dietary supplement Nutrition 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 235000021239 milk protein Nutrition 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 4
- 230000000378 dietary effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- 235000003715 nutritional status Nutrition 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000012552 review Methods 0.000 description 4
- 229920002774 Maltodextrin Polymers 0.000 description 3
- 239000005913 Maltodextrin Substances 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 3
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 3
- 229940107187 fructooligosaccharide Drugs 0.000 description 3
- 229940035034 maltodextrin Drugs 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 2
- 235000019743 Choline chloride Nutrition 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- 239000011665 D-biotin Substances 0.000 description 2
- 235000000638 D-biotin Nutrition 0.000 description 2
- 239000011626 DL-alpha-tocopherylacetate Substances 0.000 description 2
- 235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 229920001202 Inulin Polymers 0.000 description 2
- 239000002211 L-ascorbic acid Substances 0.000 description 2
- 235000000069 L-ascorbic acid Nutrition 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- 235000019484 Rapeseed oil Nutrition 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 2
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011648 beta-carotene Substances 0.000 description 2
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 2
- 235000013734 beta-carotene Nutrition 0.000 description 2
- 229960002747 betacarotene Drugs 0.000 description 2
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 2
- 229960003178 choline chloride Drugs 0.000 description 2
- 229910000365 copper sulfate Inorganic materials 0.000 description 2
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 2
- 235000000639 cyanocobalamin Nutrition 0.000 description 2
- 239000011666 cyanocobalamin Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000013872 defecation Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000013861 fat-free Nutrition 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 229960001781 ferrous sulfate Drugs 0.000 description 2
- 239000011790 ferrous sulphate Substances 0.000 description 2
- 235000003891 ferrous sulphate Nutrition 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000021552 granulated sugar Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 229940029339 inulin Drugs 0.000 description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 2
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 2
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 229940099596 manganese sulfate Drugs 0.000 description 2
- 239000011702 manganese sulphate Substances 0.000 description 2
- 235000007079 manganese sulphate Nutrition 0.000 description 2
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000004220 muscle function Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 229940067631 phospholipid Drugs 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 235000019175 phylloquinone Nutrition 0.000 description 2
- 239000011772 phylloquinone Substances 0.000 description 2
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 2
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 description 2
- 230000037081 physical activity Effects 0.000 description 2
- 229960001898 phytomenadione Drugs 0.000 description 2
- 239000001508 potassium citrate Substances 0.000 description 2
- 229960002635 potassium citrate Drugs 0.000 description 2
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 2
- 235000011082 potassium citrates Nutrition 0.000 description 2
- 235000007715 potassium iodide Nutrition 0.000 description 2
- 235000021075 protein intake Nutrition 0.000 description 2
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 2
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 2
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 2
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 2
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 2
- 235000019192 riboflavin Nutrition 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 239000002151 riboflavin Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 235000011083 sodium citrates Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229940071440 soy protein isolate Drugs 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 235000020238 sunflower seed Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940042585 tocopherol acetate Drugs 0.000 description 2
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 2
- 235000005282 vitamin D3 Nutrition 0.000 description 2
- 239000011647 vitamin D3 Substances 0.000 description 2
- 229940021056 vitamin d3 Drugs 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 2
- 229910000368 zinc sulfate Inorganic materials 0.000 description 2
- 229960001763 zinc sulfate Drugs 0.000 description 2
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 2
- PMYDPQQPEAYXKD-UHFFFAOYSA-N 3-hydroxy-n-naphthalen-2-ylnaphthalene-2-carboxamide Chemical compound C1=CC=CC2=CC(NC(=O)C3=CC4=CC=CC=C4C=C3O)=CC=C21 PMYDPQQPEAYXKD-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 description 1
- 229910021555 Chromium Chloride Inorganic materials 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 description 1
- 206010016946 Food allergy Diseases 0.000 description 1
- 208000027472 Galactosemias Diseases 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000035965 Postoperative Complications Diseases 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- VYGQUTWHTHXGQB-UHFFFAOYSA-N Retinol hexadecanoate Natural products CCCCCCCCCCCCCCCC(=O)OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 230000000386 athletic effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 108010033929 calcium caseinate Proteins 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- QSWDMMVNRMROPK-UHFFFAOYSA-K chromium(3+) trichloride Chemical compound [Cl-].[Cl-].[Cl-].[Cr+3] QSWDMMVNRMROPK-UHFFFAOYSA-K 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 230000002016 colloidosmotic effect Effects 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229960000355 copper sulfate Drugs 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960002104 cyanocobalamin Drugs 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000019007 dietary guidelines Nutrition 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 235000021196 dietary intervention Nutrition 0.000 description 1
- 235000020979 dietary recommendations Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- MHJAJDCZWVHCPF-UHFFFAOYSA-L dimagnesium phosphate Chemical compound [Mg+2].OP([O-])([O-])=O MHJAJDCZWVHCPF-UHFFFAOYSA-L 0.000 description 1
- 229910000395 dimagnesium phosphate Inorganic materials 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000011706 ferric diphosphate Substances 0.000 description 1
- 235000007144 ferric diphosphate Nutrition 0.000 description 1
- CADNYOZXMIKYPR-UHFFFAOYSA-B ferric pyrophosphate Chemical compound [Fe+3].[Fe+3].[Fe+3].[Fe+3].[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O CADNYOZXMIKYPR-UHFFFAOYSA-B 0.000 description 1
- 229940036404 ferric pyrophosphate Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 208000003243 intestinal obstruction Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229960002337 magnesium chloride Drugs 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 235000021542 oral nutrition Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 229960004839 potassium iodide Drugs 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 208000001076 sarcopenia Diseases 0.000 description 1
- 229940080237 sodium caseinate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 239000011684 sodium molybdate Substances 0.000 description 1
- 235000015393 sodium molybdate Nutrition 0.000 description 1
- TVXXNOYZHKPKGW-UHFFFAOYSA-N sodium molybdate (anhydrous) Chemical compound [Na+].[Na+].[O-][Mo]([O-])(=O)=O TVXXNOYZHKPKGW-UHFFFAOYSA-N 0.000 description 1
- 239000011655 sodium selenate Substances 0.000 description 1
- 235000018716 sodium selenate Nutrition 0.000 description 1
- 229960001881 sodium selenate Drugs 0.000 description 1
- 239000011781 sodium selenite Substances 0.000 description 1
- 235000015921 sodium selenite Nutrition 0.000 description 1
- 229960001471 sodium selenite Drugs 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 239000011755 sodium-L-ascorbate Substances 0.000 description 1
- 235000019187 sodium-L-ascorbate Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 229960000344 thiamine hydrochloride Drugs 0.000 description 1
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 1
- 239000011747 thiamine hydrochloride Substances 0.000 description 1
- UIERGBJEBXXIGO-UHFFFAOYSA-N thiamine mononitrate Chemical compound [O-][N+]([O-])=O.CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N UIERGBJEBXXIGO-UHFFFAOYSA-N 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- IWXIJAJPTFEKPL-UHFFFAOYSA-H tricalcium trisulfate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O IWXIJAJPTFEKPL-UHFFFAOYSA-H 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 238000004260 weight control Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明提供了可改善肌肉力量的组合物及其在食品中的应用。本发明首先提供一种组合物,其包括:α‑乳清蛋白,酪蛋白糖巨肽,β‑酪蛋白以及k‑酪蛋白。本发明还提供了包含所述组合物的食品,以及所述的组合物或食品在制备改善肌肉力量的食品中的应用。
Description
技术领域
本发明属于食品技术领域,具体涉及一种增加营养不良人群肌肉力量的特殊全营养医学用途食品配比方法。
背景技术
营养不良是个公共卫生问题,全世界每个国家都在采取积极的措施进行有效的防治。最近一项全球的综述报告显示,各国医院患者及社区居民营养不良的患病率和发生率均较高,尤其是高龄、消化道疾病、呼吸系统疾病、神经系统疾病和恶性肿瘤患者,发生营养不良风险更高。营养不良不仅对疾病临床结局造成不良影响,更增加了政府医疗经济成本。老年人营养不良会导致多种不良的健康后果,包括肌肉衰减、压力性溃疡、伤口愈合速度减慢、感染并发症的增加、住院率增加、住院时间增长,以及更高的死亡率和医疗成本。
口服营养补充(oral nutritional supplements,ONS)是一种有效的营养支持方式,可以加强食物中的蛋白质、碳水化合物、脂肪、矿物质和维生素等营养素含量,提供均衡的营养素以满足机体对营养物质的需求。越来越多的研究证据支持ONS可以改善社区和住院营养不良及营养不良高危患者的营养状况及临床结局。对于已经存在或有营养不良风险的患者,在饮食基础上给予ONS,可增加其能量摄入,有助于减少肌肉萎缩,并可缓慢持续增加体重,改善营养状况,降低并发症发生率和死亡率,缩短住院时间,节省医疗费用支出。特别是对于因脏器功能衰退(如肌肉消耗和功能受损、骨量减少、免疫功能低下、激素水平下降、体液电解质调节改变、手术后恢复延迟、慢性疾病、心理疾病和认知功能降低等)而导致营养不良高危风险上升的老年人群,ONS已作为一种保证充足营养摄入,维持良好生活质量的简单有效措施。然而,特殊医学用途配方食品(food for special medical purpose,FSMP)及ONS的工作刚起步,临床上对于ONS的价值依然认识不足,因此,业界一直在积极的探索FSMP对于存在营养不良风险人群的效果和安全性。根据GB 29922《食品安全国家标准特殊医学用途配方食品通则》的定义,特殊医学用途配方食品是指为了满足进食受限、消化吸收障碍、代谢紊乱或特定疾病状态人群对营养素或膳食的特殊需要,专门加工配制而成的配方食品。该类产品必须在医生或临床营养师指导下,单独食用或与其他食品配合食用。
发明内容
本发明的一个目的在于提供一种可改善肌肉力量的组合物。
本发明的另一目的在于提供包含所述组合物的食品。
本发明的另一目的在于提供所述组合物或食品在改善肌肉力量方面的相关应用。
一方面,本发明提供了一种组合物,其包括:α-乳清蛋白,酪蛋白糖巨肽,β-酪蛋白以及k-酪蛋白。
根据本发明的具体实施方案,本发明组合物中,α-乳清蛋白、酪蛋白糖巨肽、β-酪蛋白与k-酪蛋白的质量比为
1023.44~1535.16:1040.96~1561.44:2323.68~3485.52:993.76~1490.64。
根据本发明的具体实施方案,本发明组合物为蛋白组合物。
根据本发明的具体实施方案,本发明组合物,其主要原料包括乳清蛋白和酪蛋白。
根据本发明的具体实施方案,本发明组合物,其中在氨基酸水平,色氨酸、缬氨酸、异亮氨酸与亮氨酸的比例为:
0.208~0.312g:0.848~1.272g:0.808~1.212g/100g:1.456~2.184g/100g。
另一方面,本发明还提供了一种配方食品,其包括本发明所述的组合物。
根据本发明的具体实施方案,本发明的食品中,α-乳清蛋白含量1023.44~1535.16mg/100g;酪蛋白糖巨肽含量1040.96~1561.44mg/100g;β-酪蛋白含量2323.68~3485.52mg/100g;k-酪蛋白含量993.76~1490.64mg/100g。
根据本发明的具体实施方案,本发明的食品中,色氨酸含量为0.208~0.312g/100g;缬氨酸含量为0.848~1.272g/100g;异亮氨酸含量为0.808~1.212g/100g;亮氨酸含量为1.456~2.184g/100g。
另一方面,本发明还提供了所述的组合物或所述的配方食品在制备改善肌肉力量的食品中的应用。
根据本发明的具体实施方案,所述食品为特殊医学用途全营养配方食品。
本发明的产品具体可制成一种配方奶粉,具有增加肌肉力量作用,可改善营养不良人群的肌肉力量。
具体实施方式
在进一步描述本发明具体实施方案之前,应理解,本发明的保护范围不局限于下述特定的具体实施方案;还应当理解,本发明实施例中使用的术语是为了描述特定的具体实施方案,而不是为了限制本发明的保护范围。
当实施例给出数值范围时,应理解,除非本发明另有说明,每个数值范围的两个端点以及两个端点之间任何一个数值均可选用。除非另外定义,本发明中使用的所有技术和科学术语与本技术领域技术人员通常理解的意义相同。除实施例中使用的具体方法、设备、材料外,根据本技术领域的技术人员对现有技术的掌握及本发明的记载,还可以使用与本发明实施例中所述的方法、设备、材料相似或等同的现有技术的任何方法、设备和材料来实现本发明。
除非另外说明,本发明中所公开的实验方法、检测方法、制备方法均采用本技术领域常规技术。
实施例1、含有乳清蛋白和酪蛋白的特殊医学用途全营养配方食品
本实施例提供了一种特殊医学用途全营养配方食品,其中包含质量比(1-1.5):(1-1.5)的乳清蛋白和酪蛋白,其中乳清蛋白中α-乳清蛋白含量1023.44~1535.16mg/100g;酪蛋白糖巨肽1040.96~1561.44mg/100g。酪蛋白中的β-酪蛋白2323.68~3485.52mg/100g;k-酪蛋白993.76~1490.64mg/100g。在氨基酸水平,色氨酸为0.208~0.312g/100g;缬氨酸为0.848~1.272g/100g;异亮氨酸为0.808~1.212g/100g;亮氨酸为1.456~2.184g/100g。
本实施例的产品可制成一种配方食品,具有增加肌肉力量作用,可改善营养不良人群肌肉力量。
实施例2、实施例产品/市售同类产品的功效考察
实施例产品和市售同类产品的主要碳水化合物来源均为淀粉糖类(麦芽糊精、固体葡萄糖浆等),实施例产品组的主要蛋白质来源为牛乳基来源(浓缩牛奶蛋白、乳清蛋白粉),市售同类产品组的主要蛋白质来源为牛乳基来源和大豆来源(大豆分离蛋白、乳分离蛋白)。
实施例产品组配料:麦芽糊精、浓缩牛奶蛋白、乳清蛋白粉、白砂糖、葵花籽油、抗性糊精、大豆油、低聚果糖、低芥酸、菜籽油、无水奶油、醋酸视黄酯、胆钙化醇、dl-α-醋酸生育酚、植物甲萘醌、硝酸硫胺素、核黄素、盐酸吡哆醇、氰钴胺、烟酰胺、叶酸、D-泛酸钙、L-抗坏血酸、D-生物素、柠檬酸钠、柠檬酸钾、硫酸铜、氯化镁、硫酸亚铁、硫酸锌、硫酸锰、碳酸钙、磷酸三钙、碘化钾、亚硒酸钠、氯化胆碱、牛磺酸、β-胡萝卜素、磷脂。
实施例产品组中乳清蛋白与酪蛋白比例为1:1,乳清蛋白与酪蛋白占比如表1;蛋白质含量如表2,氨基酸含量如表3。
表1、实施例产品组中乳清蛋白和酪蛋白占比
蛋白质占比 | 实施例产品组(%) |
乳清蛋白占比 | 45.70% |
酪蛋白占比 | 44.50% |
表2、实施例产品组中蛋白质含量
表3、实施例产品组中氨基酸含量
氨基酸含量 | 实施例产品组(g/100g) |
色氨酸 | 0.26 |
缬氨酸 | 1.06 |
异亮氨酸 | 1.01 |
亮氨酸 | 1.82 |
市售同类产品组:淀粉糖(固体葡萄糖浆)、麦芽糊精、葵花籽油、酪蛋白酸钠、白砂糖、酪蛋白酸钙、菊粉低聚果糖混合物(菊粉、低聚果糖)、大豆油、大豆分离蛋白、乳分离蛋白、菜籽油、棕榈酸维生素A、维生素D3、dl-α-生育酚、dl-α-醋酸生育酚、混合生育酚浓缩物、植物甲萘醌、盐酸硫胺素、核黄素、盐酸吡哆醇、氰钴胺、烟酰胺、叶酸、D-泛酸钙、L-抗坏血酸、抗坏血酸棕榈酸酯、D-生物素、柠檬酸钠、氯化钠、柠檬酸钾、氯化钾、硫酸铜、氯化镁、磷酸氢镁、硫酸亚铁、焦磷酸铁、硫酸锌、硫酸锰、硫酸三钙、碘化钾、硒酸钠、氯化铬、钼酸钠、氯化胆碱、β-胡萝卜素、磷脂、食用香精、碳酸钙、磷酸氢二钾、L-抗坏血酸钠、柠檬酸、氢氧化钾。
市售同类产品组中乳清蛋白与酪蛋白占比如表4;蛋白质含量如表5,氨基酸含量如表6。
表4、市售同类产品组中乳清蛋白和酪蛋白占比
蛋白质占比 | 市售同类产品组(%) |
乳清蛋白占比 | 3.50% |
酪蛋白占比 | 80.50% |
表5、市售同类产品组中蛋白质含量
表6、市售同类产品组中氨基酸含量
氨基酸含量 | 市售同类产品组(g/100g) |
色氨酸 | 0.18 |
缬氨酸 | 0.95 |
异亮氨酸 | 0.78 |
亮氨酸 | 1.39 |
实施例产品和市售同类产品的营养成分对比见表7。
表7、实施例产品和市售同类产品的营养成分表对比
试验方法
从临床门诊、医院、社区招募135名存在营养不良或风险的中老年人作为研究对象,将其分为对照组、实施例产品组及市售同类产品组,受试者将连续食用实施例产品特医全营养配方粉、市售同类产品配方粉或给予饮食调整12周,比较三组的营养指标及生活质量。
膳食摄入建议以2016年《中国居民膳食指南》和《中国居民平衡膳食宝塔》为依据,根据受试者的三天膳食调查的结果和人体成分分析的结果,去全面的分析原因,并最后给予综合的膳食意见。三组受试者均接受研究者的膳食指导,膳食建议不会对研究科学性产生影响。
入选标准
-年龄在45周岁~80周岁;
-使用微型营养评估法(MNA)进行营养评价,选择具有营养风险和已发生营养不良的人群(MNA评分≤23.5)。
-能够口服进食;
-签署知情同意书。
排除标准
-吞咽困难或肠道梗阻;
-患有终末期疾病,或因病预期寿命≤3个月;
-严重的肝功能或肾功能受损;
-需要进行减重饮食;
-身体状况不适合食用膳食纤维者;
-最近4周接受过口服营养补充剂或参与其他临床试验;
-半乳糖血症患者,或对试验样品中的成分有过敏史,特别是乳蛋白过敏;
-其他无法完成临床试验的情况。
受试者退出标准
-受试者在试验期间出现严重不良反应;
-受试者在试验期间使用了对试验结果有影响的营养药物,如口服营养补充剂等;
-受试者未按试验方案要求服用营养补充剂,频率大于每周2次;
-其他研究者判定不适合继续进行研究的情况;
-受试者主动要求退出临床试验;
-受试者未明确提出退出临床试验,但拒绝使用营养补充剂。
营养不良的评估
MNA量表:根据《中国老年患者肠外肠内营养应用指南(2020版)》的推荐5,“老年患者营养不良发生率高,推荐常规进行营养筛查;推荐MNA-SF和NRS2002营养筛查工具”。中华医学会肠外肠内营养学分会2017年发表的《成人口服营养补充专家共识》中表明,NRS2002是住院患者营养风险筛查首选工具,MNA是一种评价老年人营养状况的简单快速的方法,其内容包括人体测量、整体评定、膳食问卷以及主观评定等18项内容,具有很高的准确性。是老年人首选的营养评价工具,也更加适合社区老年人的营养评估。
体重相关指标
身体质量指数(BMI):体质指数是国际通行评价人体胖瘦情况的指标。加拿大皇后大学Janssen等进行的研究中,校正腰围指标后,发现体质指数(BMI)与死亡风险呈负相关,BMI每增加一个标准差,死亡风险下降21%。
非意向减重百分数:是指受试者在无意进行体重控制的情况下,自身体重的变化情况。本指标在临床研究常用于评价受试人群在接收临床干预后,体重的变化情况。
无脂体重:又称瘦体重,其中肌肉和骨骼占有较大比重,由于短期内人体骨骼的重量变化不大,无脂体重的变化能更好的反映受试者肌肉量的变化。
肌肉力量相关指标
握力:在所有的肌肉功能测试中,握力测量作为一种简单、无创的上肢肌力指标。因此握力指标受到重视,很适合临床使用。由于肌肉功能对营养剥夺反应较早,握力也已成为营养状况的重要标志,并越来越多地被用作营养干预研究的结果变量。此外握力可预测多种关键结局,如术后并发症、死亡率、功能下降等的重要指标,对于老年人群的意义重大。
小腿围和上臂围:是评价老年人营养不良状况和预测死亡的重要指标,与体质指数相关性高,具有同等重要性。
功能限制问卷
简易五项评分问卷(SARC-F):主要评价受试者的日常活动能力,是一种常用的老年人肌肉衰减症快速简易诊断手段。
老年人体力活动量表
老年人体育活动量表(PASE):主要评价受试者的体力活动能力,包括评估问题和评分。PASE量表在全球的流行病学研究中常用于评价老年人的体育锻炼水平。
生活质量问卷—欧洲五维健康量表(EQ-5D)
欧洲五维健康量表(EQ-5D):是由欧洲生存质量学会(Euro QoL Group)制订的,一种多维健康相关生存质量测量法,既可以用于健康人群评价特定人群的健康状态,也可以用于患病人群评价疾病导致的健康状态的下降。
胃肠道安全性
排便和胃肠道反应与膳食密切相关,如过量摄入蛋白质可能会产生便秘,膳食纤维可以帮助胃肠道蠕动,促进排便等。
膳食调查
膳食回顾法:又称24小时回顾法,使被调查对象回顾和描述在调查时刻以前24小时内摄入的所有食物的数量和种类,借助食物模型、家具量具或食物图谱对其食物摄入量进行计算和评价。膳食回顾法常用于评价人群的膳食摄入量。
血常规和血生化指标
血清总蛋白具有维持血液正常胶体渗透压和pH、运输多种代谢物、调节被运输物质的生理作用和解除其毒性、免疫作用以及营养作用等多种功能,血清总蛋白不仅可用于机体营养状态的监测,还可用于疾病的诊断及鉴别诊断;血红蛋白是评价老年人贫血程度的指标,血红蛋白的升高,标志这老年人贫血状态的改善;白蛋白是人体血浆中最主要的蛋白质,维持机体营养与渗透压;白细胞计数、淋巴细胞计数、CRP均为机体重要的炎症指标;血尿素氮是蛋白质代谢的重要指标,血尿素氮低可能标志机体蛋白质摄入不足。
结果与分析:
实施例产品组和市售同类产品组的肌肉力量相关指标变化情况见表8。
表8、实施例产品组和市售同类产品组的肌肉力量相关指标变化情况对比
实验结果表明,干预4周时实施例产品组的左手握力增长明显高于市售同类产品组,差值为1.794kg,差异具有统计学意义(P=0.027<0.05);12周时实施例产品组的右小腿围增长明显高于市售同类产品组,差值为0.369cm,差异具有统计学意义(P=0.034<0.05)。
上述的对实施例的描述是为便于该技术领域的普通技术人员能理解和使用发明。熟悉本领域技术的人员显然可以容易地对这些实施例做出各种修改,并把在此说明的一般原理应用到其他实施例中而不必经过创造性的劳动。因此,本发明不限于上述实施例,本领域技术人员根据本发明的揭示,不脱离本发明范畴所做出的改进和修改都应该在本发明的保护范围之内。
Claims (10)
1.一种组合物,其包括:α-乳清蛋白,酪蛋白糖巨肽,β-酪蛋白以及k-酪蛋白。
2.根据权利要求1所述的组合物,其中,α-乳清蛋白、酪蛋白糖巨肽、β-酪蛋白与k-酪蛋白的质量比为1023.44~1535.16:1040.96~1561.44:2323.68~3485.52:993.76~1490.64。
3.根据权利要求1或2所述的组合物,其为蛋白组合物。
4.根据权利要求1-3任一项所述的组合物,其主要原料包括乳清蛋白和酪蛋白。
5.根据权利要求1-4任一项所述的组合物,其中在氨基酸水平,色氨酸、缬氨酸、异亮氨酸与亮氨酸的比例为:
0.208~0.312g:0.848~1.272g:0.808~1.212g/100g:1.456~2.184g/100g。
6.一种配方食品,其包括权利要求1-5任一项所述的组合物。
7.根据权利要求6所述的配方食品,其中,α-乳清蛋白含量1023.44~1535.16mg/100g;酪蛋白糖巨肽含量1040.96~1561.44mg/100g;β-酪蛋白含量2323.68~3485.52mg/100g;k-酪蛋白含量993.76~1490.64mg/100g。
8.根据权利要求6所述的配方食品,其中,色氨酸含量为0.208~0.312g/100g;缬氨酸含量为0.848~1.272g/100g;异亮氨酸含量为0.808~1.212g/100g;亮氨酸含量为1.456~2.184g/100g。
9.权利要求1-5任一项所述的组合物或权利要求6-8任一项所述的配方食品在制备改善肌肉力量的食品中的应用。
10.根据权利要求9所述的应用,其中,所述食品为特殊医学用途全营养配方食品;优选地,所述食品为中老年人特殊医学用途全营养配方食品。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211528940.9A CN115736259A (zh) | 2022-11-30 | 2022-11-30 | 可改善肌肉力量的组合物及其在食品中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211528940.9A CN115736259A (zh) | 2022-11-30 | 2022-11-30 | 可改善肌肉力量的组合物及其在食品中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115736259A true CN115736259A (zh) | 2023-03-07 |
Family
ID=85342066
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211528940.9A Pending CN115736259A (zh) | 2022-11-30 | 2022-11-30 | 可改善肌肉力量的组合物及其在食品中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115736259A (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105120689A (zh) * | 2013-04-15 | 2015-12-02 | 雀巢产品技术援助有限公司 | 乳清蛋白质与电肌肉刺激组合的用途 |
CN107809916A (zh) * | 2015-06-26 | 2018-03-16 | 维塔尔奈克斯特有限责任公司 | 用于治疗营养不良的组合物和方法 |
CN108348553A (zh) * | 2015-11-20 | 2018-07-31 | 雀巢产品技术援助有限公司 | 使用乳清蛋白以改善或维持肌肉质量的方法 |
CN112741155A (zh) * | 2021-01-19 | 2021-05-04 | 海普诺凯营养品有限公司 | 一种养颜营养粉及其制备方法 |
WO2022195025A1 (en) * | 2021-03-17 | 2022-09-22 | N.V. Nutricia | Liquid nutritional composition suitable for muscle function |
-
2022
- 2022-11-30 CN CN202211528940.9A patent/CN115736259A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105120689A (zh) * | 2013-04-15 | 2015-12-02 | 雀巢产品技术援助有限公司 | 乳清蛋白质与电肌肉刺激组合的用途 |
US20180169187A1 (en) * | 2015-06-25 | 2018-06-21 | Vitalnext B.V. | Compositions and methods for the treatment of malnutrition |
CN107809916A (zh) * | 2015-06-26 | 2018-03-16 | 维塔尔奈克斯特有限责任公司 | 用于治疗营养不良的组合物和方法 |
CN108348553A (zh) * | 2015-11-20 | 2018-07-31 | 雀巢产品技术援助有限公司 | 使用乳清蛋白以改善或维持肌肉质量的方法 |
CN112741155A (zh) * | 2021-01-19 | 2021-05-04 | 海普诺凯营养品有限公司 | 一种养颜营养粉及其制备方法 |
WO2022195025A1 (en) * | 2021-03-17 | 2022-09-22 | N.V. Nutricia | Liquid nutritional composition suitable for muscle function |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Sauberlich et al. | Folate requirement and metabolism in nonpregnant women | |
CN101061860B (zh) | 富含亮氨酸的营养组合物 | |
Shetty | Malnutrition and undernutrition | |
Hoque et al. | Comprehensive guide to vitamin and mineral sources with their requirements | |
Mironenko et al. | Magnesium (Mg, Magnesium)–description, effect on the body, the best sources of magnesium | |
Shetty | Malnutrition and undernutrition | |
Faizan et al. | Nutrition and hydration requirements in children and adults | |
Riess et al. | Ascorbic acid deficiency in bariatric surgical population | |
Stotts | Nutritional assessment and support | |
Ayling | Clinical biochemistry of nutrition | |
Holliday et al. | Nutritional management of chronic renal disease | |
Trujillo et al. | Nutritional assessment in the critically ill | |
CN115736259A (zh) | 可改善肌肉力量的组合物及其在食品中的应用 | |
RU2147228C1 (ru) | Способ лечения ожирения | |
Watanabe et al. | A Cross-Sectional Study on the Effects of Long Term Very Low Protein Diets in Patients with Chronic Kidney Disease Serum and Urine DEXA and Amino Acid Profiles | |
Pasquale et al. | Nutrition support | |
Kronik et al. | Vitamin Deficiencies–Diagnosis and Treatment | |
RAHAL et al. | Diagnostic and management strategies of undernutrition in the elderly: a review | |
Topçuoğlu et al. | Use of Oral Nutritional Supplements in Neurology: General Principles, Special Practices | |
Institute of Medicine (US) Standing Committee on the Scientific Evaluation of Dietary Reference Intakes | Thiamin | |
Safarova et al. | THE ROLE OF IRON IN THE HUMAN ORGANISM | |
Arulappan et al. | Zinc in Child Health | |
Baines et al. | Undernutrition in the community | |
CN117297079A (zh) | 一种减肥代餐粉组合物及其应用 | |
CN117243369A (zh) | 一种特殊医学用途配方食品满元营养液及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |